Stocks Merck & Co Inc

  • GlaxoSmithKline

    The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.

  • A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.

  • webxtra_thumb.jpg

    In this Web Extra, we bring you the day's biggest winners and losers. Find out why shares of Philip Morris and Merck popped while AT&T and Micron dropped.

  • Don't get so swept up in trying to predict where specific stocks are going that you ignore what they're saying about the market as a whole.

  • Forget politics. Cramer has a better way to judge the president's performance: stocks.

  • Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.

  • Nasonex Ad

    I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.

  • Stocks ended higher Tuesday as investors were encouraged by comments from Treasury Secretary Tim Geithner that most banks are well capitalized.

  • Stocks turned mixed Tuesday as another wave of disappointing earnings news weighed on the market but tech stocks shined bright.

  • US stock index futures turned lower ahead of the open Tuesday after key corporate earnings sounded a note of caution for investors.

  • webxtra_thumb.jpg

    In this Web Extra, the traders game Coca-Cola, Merck, Capital One and a slew of other companies about to report earnings.

  • CNBC’s Mike Huckman is keeping a close eye on Big Pharma earnings. And he suggests you do the same - because he's spotted a devil the details.

  • Next week you could nearly drown in data, considering the flood of earnings reports that are coming. But don’t panic, our traders will keep you afloat.

  • Stocks closed higher despite some selling in the final half hour of trading, giving the market its sixth straight weekly gain and its longest weekly winning streak since 2007.

  • With stocks rallying for 5 weeks in a row now, dividend yields are falling back to Earth.  The average dividend yield of the Dow 30 has fallen over 25% since the rally began in early March.  See how the 30 companies in the Dow compare.

  • Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.

  • Stocks fell Monday amid doubts over the health of the banking industry and the apparent collapse of a major deal in the technology sector.

  • Breakthrough diabetes treatments may be on the horizon. What companies stand to win?

  • Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.

  • Stocks capped a relatively good week with a thud Friday as investors locked in profits.